A Randomised, Double-blind, Dose Finding, Repeat Dose Phase II Multicentre Study of ODX for the Treatment of Patients With Castration Resistant Prostate Cancer (CRPC) and Skeletal Metastases
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Alendronic acid/guanidine dextran conjugate (Primary)
- Indications Bone metastases
- Focus Biomarker; Therapeutic Use
- Sponsors DexTech Medical
- 29 Aug 2024 Status changed from active, no longer recruiting to completed.
- 20 Dec 2022 Results published in the European Journal of Cancer
- 30 Jul 2020 This trial is completed in Latvia according to European Clinical Trials Database record.